Statement: the primary trial and the secondary trial only record 2 of the same adverse events.
Primary_evidence: Adverse Events 1:   Total: 10/14 (71.43%)   Hemoglobin 2/14 (14.29%)   Lymphopenia 1/14 (7.14%)   Cardiac ischemia/infarction 1/14 (7.14%)   Hypertension 2/14 (14.29%)   Hypotension 1/14 (7.14%)   Constipation 1/14 (7.14%)   Diarrhea 1/14 (7.14%)   Heartburn/dyspepsia 1/14 (7.14%)   Fatigue (asthenia, lethargy, malaise) 2/14 (14.29%)   Rigors/chills 1/14 (7.14%)
Secondary_evidence: Adverse Events 1:   Total: 96/162 (59.26%)   Cardiac disorders - Other, specify 2/162 (1.23%)   Diarrhea 1/162 (0.62%)   Mucositis oral 2/162 (1.23%)   Nausea 1/162 (0.62%)   Fatigue 6/162 (3.70%)   Breast infection 2/162 (1.23%)   Soft tissue infection 1/162 (0.62%)   Lymphocyte count decreased 2/162 (1.23%)   Neutrophil count decreased 78/162 (48.15%)   Hypertension 1/162 (0.62%)